{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:03:19Z","timestamp":1782860599937,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100019265","name":"Yuhan","doi-asserted-by":"publisher","award":["IIT-061"],"award-info":[{"award-number":["IIT-061"]}],"id":[{"id":"10.13039\/100019265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019265","name":"Yuhan","doi-asserted-by":"publisher","award":["IIT-061"],"award-info":[{"award-number":["IIT-061"]}],"id":[{"id":"10.13039\/100019265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019265","name":"Yuhan","doi-asserted-by":"publisher","award":["IIT-061"],"award-info":[{"award-number":["IIT-061"]}],"id":[{"id":"10.13039\/100019265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019265","name":"Yuhan","doi-asserted-by":"publisher","award":["IIT-061"],"award-info":[{"award-number":["IIT-061"]}],"id":[{"id":"10.13039\/100019265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04871-w","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:57:41Z","timestamp":1778039861000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating miR-184 and miR-206 as predictive biomarkers for early recurrence in HBV-related hepatocellular carcinoma: a prospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Sang-Hoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunjin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunyoung","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Hun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"4871_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3350\/cmh.2022.0321","volume":"29","author":"Y Cho","year":"2023","unstructured":"Cho Y, Kim BH, Park JW. The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea. Clin Mol Hepatol. 2023;29:99\u2013101. https:\/\/doi.org\/10.3350\/cmh.2022.0321.","journal-title":"Clin Mol Hepatol"},{"key":"4871_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.17998\/jlc.2024.03.13","volume":"24","author":"DY Kim","year":"2024","unstructured":"Kim DY. Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. J Liver Cancer. 2024;24:62\u201370. https:\/\/doi.org\/10.17998\/jlc.2024.03.13.","journal-title":"J Liver Cancer"},{"key":"4871_CR3","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.2147\/JHC.S556306","volume":"12","author":"WL Luo","year":"2025","unstructured":"Luo WL, Wang QB, Li YK, Liang YB, Li J, Chen XM, et al. Impact of middle hepatic vein resection during hemihepatectomy on surgical outcomes and long-term prognosis in hepatocellular carcinoma: a retrospective study. J Hepatocell Carcinoma. 2025;12:2681\u201392. https:\/\/doi.org\/10.2147\/JHC.S556306.","journal-title":"J Hepatocell Carcinoma"},{"key":"4871_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.14701\/ahbps.24-103","volume":"28","author":"SH Kim","year":"2024","unstructured":"Kim SH, Kim KH, Na BG, Kim SM, Oh RK. Primary treatments for solitary hepatocellular carcinoma\u2009\u2264\u20093\u00a0cm: a systematic review and network meta-analysis. Ann Hepatobiliary Pancreat Surg. 2024;28:397\u2013411. https:\/\/doi.org\/10.14701\/ahbps.24-103.","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"4871_CR5","doi-asserted-by":"publisher","first-page":"100145","DOI":"10.1016\/j.jlb.2024.100145","volume":"4","author":"H Aguilar","year":"2024","unstructured":"Aguilar H, L\u00f3pez-Rold\u00e1n B, Vilalta-Lacarra A, Alkorta-Aranburu G, Claramunt R, L\u00f3pez-Guerrero JA, et al. Liquid biopsy for monitoring minimal residual disease in localized and locally-advanced non-small cell lung cancer after radical-intent treatment. J Liq Biopsy. 2024;4:100145. https:\/\/doi.org\/10.1016\/j.jlb.2024.100145.","journal-title":"J Liq Biopsy"},{"key":"4871_CR6","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.21037\/tlcr-22-390","volume":"11","author":"M Verz\u00e8","year":"2022","unstructured":"Verz\u00e8 M, Pluchino M, Leonetti A, Corian\u00f2 M, Bonatti F, Armillotta MP, et al. Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review. Transl Lung Cancer Res. 2022;11:2588\u2013600. https:\/\/doi.org\/10.21037\/tlcr-22-390.","journal-title":"Transl Lung Cancer Res"},{"key":"4871_CR7","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1158\/1078-0432.CCR-24-0226","volume":"30","author":"S Slater","year":"2024","unstructured":"Slater S, Bryant A, Aresu M, Begum R, Chen HC, Peckitt C, et al. Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC Part B study. Clin Cancer Res. 2024;30:3459\u201369. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0226.","journal-title":"Clin Cancer Res"},{"key":"4871_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s12609-023-00489-z","volume":"15","author":"JJ Sears","year":"2023","unstructured":"Sears JJ, Davis AA. Clinical applications for liquid biopsy assessment of minimal residual disease in breast cancer. Curr Breast Cancer Rep. 2023;15:252\u201365. https:\/\/doi.org\/10.1007\/s12609-023-00489-z.","journal-title":"Curr Breast Cancer Rep"},{"key":"4871_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s10528-024-11001-2","author":"B Zhang","year":"2025","unstructured":"Zhang B, Ma X, Zhou Y, Zhu B, Yu J, Liu H, et al. Diagnostic value of circulating microRNAs for hepatocellular carcinoma: results of a meta-analysis and validation. Biochem Genet. 2025. https:\/\/doi.org\/10.1007\/s10528-024-11001-2.","journal-title":"Biochem Genet"},{"key":"4871_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-54795-2","volume":"14","author":"GI Sayed","year":"2024","unstructured":"Sayed GI, Solyman M, El Gedawy G, Moemen YS, Aboul-Ella H, Hassanien AE. Circulating miRNA biomarkers for early detection of hepatocellular carcinoma in Egyptian patients based on machine learning algorithms. Sci Rep. 2024;14:1\u201319. https:\/\/doi.org\/10.1038\/s41598-024-54795-2.","journal-title":"Sci Rep"},{"key":"4871_CR11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/hepr.13338","volume":"49","author":"M Chuma","year":"2019","unstructured":"Chuma M, Toyoda H, Matsuzaki J, Saito Y, Kumada T, Tada T, et al. Circulating microRNA-1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma. Hepatol Res. 2019;49:810\u201322. https:\/\/doi.org\/10.1111\/hepr.13338.","journal-title":"Hepatol Res"},{"key":"4871_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-1043-x","volume":"18","author":"Q Ye","year":"2019","unstructured":"Ye Q, Ling S, Zheng S, Xu X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019;18:1\u201313. https:\/\/doi.org\/10.1186\/s12943-019-1043-x.","journal-title":"Mol Cancer"},{"key":"4871_CR13","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1136\/gutjnl-2019-320282","volume":"69","author":"J Von Felden","year":"2020","unstructured":"Von Felden J, Garcia-Lezana T, Schulze K, Losic B, Villanueva A. Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut. 2020;69:2025\u201334. https:\/\/doi.org\/10.1136\/gutjnl-2019-320282.","journal-title":"Gut"},{"key":"4871_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2026.1714314","volume":"17","author":"J Li","year":"2026","unstructured":"Li J, Liang YB, Chen XM, Ou ZY, Wang QB, Luo WL, et al. Prognostic value of lymphatic vessel density in the capsule of early-stage hepatocellular carcinoma: implications for postoperative recurrence risk. Front Immunol. 2026;17:1\u201312. https:\/\/doi.org\/10.3389\/fimmu.2026.1714314.","journal-title":"Front Immunol"},{"key":"4871_CR15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s12072-023-10594-x","volume":"18","author":"A Huang","year":"2024","unstructured":"Huang A, Guo DZ, Zhang X, Sun Y, Zhang SY, Zhang X, et al. Serial circulating tumor DNA profiling predicts tumor recurrence after liver transplantation for liver cancer. Hepatol Int. 2024;18:254\u201364. https:\/\/doi.org\/10.1007\/s12072-023-10594-x.","journal-title":"Hepatol Int"},{"key":"4871_CR16","doi-asserted-by":"publisher","first-page":"7190","DOI":"10.7150\/jca.59612","volume":"12","author":"A Huang","year":"2021","unstructured":"Huang A, Guo DZ, Wang YP, Yang GH, Sun QM, Zhang X, et al. Plasma microRNA panel predicts early tumor recurrence in patients with hepatocellular carcinoma after liver transplantation. J Cancer. 2021;12:7190\u2013200. https:\/\/doi.org\/10.7150\/jca.59612.","journal-title":"J Cancer"},{"key":"4871_CR17","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/SLA.0000000000006386","volume":"280","author":"CJ Wehrle","year":"2024","unstructured":"Wehrle CJ, Hong H, Kamath S, Schlegel A, Fujiki M, Hashimoto K, et al. Tumor mutational burden from circulating tumor DNA predicts recurrence of hepatocellular carcinoma after resection: an emerging biomarker for surveillance. Ann Surg. 2024;280:504\u201313. https:\/\/doi.org\/10.1097\/SLA.0000000000006386.","journal-title":"Ann Surg"},{"key":"4871_CR18","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/liv.14734","volume":"41","author":"PX Wang","year":"2021","unstructured":"Wang PX, Xu Y, Sun YF, Cheng JW, Zhou KQ, Wu SY, et al. Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. Liver Int. 2021;41:562\u201373. https:\/\/doi.org\/10.1111\/liv.14734.","journal-title":"Liver Int"},{"key":"4871_CR19","doi-asserted-by":"publisher","first-page":"1353547","DOI":"10.3389\/fmolb.2024.1353547","volume":"11","author":"E Alemayehu","year":"2024","unstructured":"Alemayehu E, Fasil A, Ebrahim H, Mulatie Z, Bambo GM, Gedefie A, et al. Circulating microRNAs as promising diagnostic biomarkers for hepatocellular carcinoma: a systematic review and meta-analysis. Front Mol Biosci. 2024;11:1353547. https:\/\/doi.org\/10.3389\/fmolb.2024.1353547.","journal-title":"Front Mol Biosci"},{"key":"4871_CR20","doi-asserted-by":"publisher","first-page":"9853","DOI":"10.3748\/wjg.v21.i34.9853","volume":"21","author":"YC Zhang","year":"2015","unstructured":"Zhang YC, Xu Z, Zhang TF, Wang YL. Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma. World J Gastroenterol. 2015;21:9853\u201362. https:\/\/doi.org\/10.3748\/wjg.v21.i34.9853.","journal-title":"World J Gastroenterol"},{"key":"4871_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-46872-8","volume":"9","author":"Y Jin","year":"2019","unstructured":"Jin Y, Wong YS, Goh BKP, Chan CY, Cheow PC, Chow PKH, et al. Circulating microRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma. Sci Rep. 2019;9:1\u201312. https:\/\/doi.org\/10.1038\/s41598-019-46872-8.","journal-title":"Sci Rep"},{"key":"4871_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s13105-025-01104-8","author":"L Hosseinzadeh","year":"2025","unstructured":"Hosseinzadeh L, Jalilian F, Kalhori MR, Alibakhshi R, Kalhori AA, Karami M. miR-184 in hepatocellular carcinoma: a promising therapeutic target. J Physiol Biochem. 2025. https:\/\/doi.org\/10.1007\/s13105-025-01104-8.","journal-title":"J Physiol Biochem"},{"key":"4871_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2026.5729","volume":"57","author":"XM Chen","year":"2026","unstructured":"Chen XM, Liang YB, Zuo JX, Yang ZS, Zhang LY, Zhang XY, et al. ZG16B: a key regulator of tumor progression and immune microenvironment modulation in cancer (review). Int J Mol Med. 2026;57:1\u201313. https:\/\/doi.org\/10.3892\/ijmm.2026.5729.","journal-title":"Int J Mol Med"},{"key":"4871_CR24","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.3748\/wjg.v30.i41.4503","volume":"30","author":"D Ramoni","year":"2024","unstructured":"Ramoni D, Montecucco F. MicroRNA-206 as a promising epigenetic approach to modulate tumor-associated macrophages in hepatocellular carcinoma. World J Gastroenterol. 2024;30:4503\u20138. https:\/\/doi.org\/10.3748\/wjg.v30.i41.4503.","journal-title":"World J Gastroenterol"},{"key":"4871_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.hpb.2022.05.234","volume":"26","author":"SH Kim","year":"2022","unstructured":"Kim SH, Hwang S, Song GW, Jung DH, Moon DB, Yang JD, et al. Identification of key genes and carcinogenic pathways in hepatitis B virus-associated hepatocellular carcinoma through bioinformatics analysis. Ann Hepatobiliary Pancreat Surg. 2022;26:58\u201368. https:\/\/doi.org\/10.1016\/j.hpb.2022.05.234.","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"4871_CR26","doi-asserted-by":"publisher","first-page":"e40082","DOI":"10.1097\/MD.0000000000040082","volume":"103","author":"M Zhu","year":"2024","unstructured":"Zhu M, Gao Y, Zhu K, Yuan Y, Bai H, Meng L. Exosomal miRNA as biomarker in cancer diagnosis and prognosis: a review. Med (Baltim). 2024;103:e40082. https:\/\/doi.org\/10.1097\/MD.0000000000040082.","journal-title":"Med (Baltim)"},{"key":"4871_CR27","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s11033-020-06050-w","volume":"48","author":"JA Jim\u00e9nez-Avalos","year":"2021","unstructured":"Jim\u00e9nez-Avalos JA, Fern\u00e1ndez-Mac\u00edas JC, Gonz\u00e1lez-Palomo AK. Circulating exosomal microRNAs: new non-invasive biomarkers of non-communicable disease. Mol Biol Rep. 2021;48:961\u20137. https:\/\/doi.org\/10.1007\/s11033-020-06050-w.","journal-title":"Mol Biol Rep"},{"key":"4871_CR28","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3390\/cells13181562","volume":"13","author":"AAI Hassanin","year":"2024","unstructured":"Hassanin AAI, Ramos KS. Circulating exosomal miRNA profiles in non-small cell lung cancers. Cells. 2024;13:1562. https:\/\/doi.org\/10.3390\/cells13181562.","journal-title":"Cells"},{"key":"4871_CR29","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1002\/1878-0261.13709","volume":"19","author":"Y Hayashi","year":"2025","unstructured":"Hayashi Y, Millen JC, Ramos RI, Linehan JA, Wilson TG, Hoon DSB, et al. Cell-free and extracellular vesicle microRNAs with clinical utility for solid tumors. Mol Oncol. 2025;19:1935\u201367. https:\/\/doi.org\/10.1002\/1878-0261.13709.","journal-title":"Mol Oncol"},{"key":"4871_CR30","doi-asserted-by":"publisher","first-page":"e0130677","DOI":"10.1371\/journal.pone.0130677","volume":"10","author":"Q Liao","year":"2015","unstructured":"Liao Q, Han P, Huang Y, Wu Z, Chen Q, Li S, et al. Potential role of circulating microRNA-21 for hepatocellular carcinoma diagnosis: a meta-analysis. PLoS ONE. 2015;10:e0130677. https:\/\/doi.org\/10.1371\/journal.pone.0130677.","journal-title":"PLoS ONE"},{"key":"4871_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2011.04.026","volume":"56","author":"Y Tomimaru","year":"2012","unstructured":"Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol. 2012;56:167\u201375. https:\/\/doi.org\/10.1016\/j.jhep.2011.04.026.","journal-title":"J Hepatol"},{"key":"4871_CR32","doi-asserted-by":"publisher","first-page":"108080","DOI":"10.1016\/j.bioorg.2024.108080","volume":"154","author":"Z Niu","year":"2025","unstructured":"Niu Z, Shi Z, Wu G, Liu Y, Xie W, Liu F, et al. Discovery of a novel CDK4\/6 and HDAC dual-targeting agent for the treatment of hepatocellular carcinoma. Bioorg Chem. 2025;154:108080. https:\/\/doi.org\/10.1016\/j.bioorg.2024.108080.","journal-title":"Bioorg Chem"},{"key":"4871_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-022-02152-w","volume":"22","author":"Z Wei","year":"2022","unstructured":"Wei Z, Zhou X, Lan C, Huang H, Liao X, Mo S, et al. Clinical implications and molecular mechanisms of cyclin-dependent kinases 4 for patients with hepatocellular carcinoma. BMC Gastroenterol. 2022;22:1\u201317. https:\/\/doi.org\/10.1186\/s12876-022-02152-w.","journal-title":"BMC Gastroenterol"},{"key":"4871_CR34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2174\/0109298673279399240102095116","volume":"32","author":"F Lai","year":"2024","unstructured":"Lai F, Fang Y, Cheng C, Zhong X, Zheng W, Lan S, et al. CDK4 as a prognostic marker of hepatocellular carcinoma and CDK4 inhibitors as potential therapeutics. Curr Med Chem. 2024;32:343\u201358. https:\/\/doi.org\/10.2174\/0109298673279399240102095116.","journal-title":"Curr Med Chem"},{"key":"4871_CR35","doi-asserted-by":"publisher","unstructured":"Huang L, Yuan W, Li X, Liu Y, Wan R, Ma X, et al. CDK4\/6-mediated phosphorylation of DUB3 promotes YAP1 stability and hepatocellular carcinoma progression. Cell Death Discov. 2025;11. https:\/\/doi.org\/10.1038\/s41420-025-02493-x.","DOI":"10.1038\/s41420-025-02493-x"},{"key":"4871_CR36","doi-asserted-by":"publisher","first-page":"11728","DOI":"10.1080\/21655979.2021.2006942","volume":"12","author":"JN Zhang","year":"2021","unstructured":"Zhang JN, Wei F, Lei LH, Yang Y, Yang Y, Zhou WP. Cyclin-dependent kinase 4 is expected to be a therapeutic target for hepatocellular carcinoma metastasis using integrated bioinformatic analysis. Bioengineered. 2021;12:11728\u201339. https:\/\/doi.org\/10.1080\/21655979.2021.2006942.","journal-title":"Bioengineered"},{"key":"4871_CR37","doi-asserted-by":"publisher","unstructured":"Gan Y, Zhu L, Li Y, Ge R, Tian J, Chen Y, et al. AdipoR1 enhances the radiation resistance via ESR1\/CCNB1IP1\/cyclin B1 pathway in hepatocellular carcinoma cells. Mol Med. 2025;31. https:\/\/doi.org\/10.1186\/s10020-025-01065-0.","DOI":"10.1186\/s10020-025-01065-0"},{"key":"4871_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2021.777834","volume":"11","author":"M Bhat","year":"2021","unstructured":"Bhat M, Pasini E, Pastrello C, Angeli M, Baciu C, Abovsky M, et al. Estrogen receptor 1 inhibition of Wnt\/beta-catenin signaling contributes to sex differences in hepatocarcinogenesis. Front Oncol. 2021;11:1\u201312. https:\/\/doi.org\/10.3389\/fonc.2021.777834.","journal-title":"Front Oncol"},{"key":"4871_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.bbrc.2022.07.047","volume":"623","author":"X Hu","year":"2022","unstructured":"Hu X, Pan H, Zhou S, Pang Q, Wang Y, Zhu C, et al. HS1BP3, transcriptionally regulated by ESR1, promotes hepatocellular carcinoma progression. Biochem Biophys Res Commun. 2022;623:111\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2022.07.047.","journal-title":"Biochem Biophys Res Commun"},{"key":"4871_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s11010-020-03927-z","volume":"476","author":"L Wang","year":"2021","unstructured":"Wang L, Cui M, Cheng D, Qu F, Yu J, Wei Y, et al. miR-9-5p facilitates hepatocellular carcinoma cell proliferation, migration and invasion by targeting ESR1. Mol Cell Biochem. 2021;476:575\u201383. https:\/\/doi.org\/10.1007\/s11010-020-03927-z.","journal-title":"Mol Cell Biochem"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04871-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04871-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04871-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:30:06Z","timestamp":1782858606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04871-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4871"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04871-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9024910\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical standards of the Institutional Review Board of Asan Medical Center and the principles of the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of Asan Medical Center, Seoul, Korea (IRB No. 2023-0048). Written informed consent was obtained from all participants prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"390"}}